Advanced Optimal Pulse Technology Treats Rosacea

The AOPT-LTL treatment produced satisfactory therapeutic effects on erythema and flushing of patients with erythematotelangiectatic rosacea.

Erythematotelangiectatic rosacea (ETR) can be safely and effectively treated with advanced optimal pulse technology (OPT) with low energy, 3 pulses, and long pulse width (AOPT-LTL), according to study findings published in the Journal of Cosmetic Dermatology.

Researchers sought to examine the practicality and underlying molecular mechanisms of AOPT-LTL treatment using a rosacea-like mouse model and to investigate the safety and efficacy of this treatment in patients with ETR.

They conducted a prospective study that included 23 patients (87% women; 31.8±7.6 years of age) diagnosed with ETR (mean duration 2.73±1.25 years) and recruited from the Department of Medical Cosmetology of Yanbian University Hospital, and Suzhou Mylike Cosmetic Hospital, both in China. Exclusions included patients with intense sun exposure in the past month, laser treatment in the past 3 months, scar diathesis, autoimmune diseases or severe organic diseases, history of photosensitive reaction or received photosensitizing therapies in the past month, women who were pregnant and lactating.

Participants received varying numbers of treatment (6-10 times, mean 8.03±1.67) at 2-week intervals based on baseline disease severity. Effects were evaluated by comparison of clinical photographs at baseline, 1 week, and 3 months following treatment, along with red value, global flushing symptom scores (GFSS, baseline 39% moderate, 61% severe) and clinician erythema assessment (CEA, baseline 22% mild, 69% moderate, 9% severe) scores.

It is a safe and effective treatment for ETR and is worthy of clinical application and promotion.

Before and after treatment photographs suggested to researchers that patients improved following treatment. Some patients showed slight recurrence in the 3-month follow-up photographs but still significantly improved from baseline. Following 1 week of treatment, red value scores decreased (average) (-22.17), GFSS (-5.3), and CEA (-1.75) compared with baseline, and at 3 months red value (-17.5), GFSS (-4.24), and CEA (-1.43) compared with baseline.

In the 23 patients with ETR treated with AOPT-LTL, researchers observed satisfactory therapeutic effects on flushing and erythema. They noticed no serious adverse events.

Treatment with AOPT-LTL in LL-37-induced rosacea-like mice (once every 24 hours, 3 times) was accomplished to investigate efficacy and underlying mechanisms. Following this treatment, researchers found the inflammatory cell infiltration, vascular abnormalities, and rosacea-like phenotype were significantly improved. They noted the expression of core molecules of rosacea was significantly inhibited, and the decreases in capillary density and erythema scores in the test group were more significant than those in the control group (P <.01).

Study limitations include lack of patient control group, underpowered sample size, and short follow-up time.

Researchers concluded “AOPT-LTL treatment can improve the symptoms of ETR by regulating the immune response and neurovascular abnormalities.” They added “It is a safe and effective treatment for ETR and is worthy of clinical application and promotion.”

References:

Yuan J, Gao Y, Pi L, et al. Novel technique for rosacea treatment using optimal pulse technology: in vivo and clinical studies. J Cosmet Dermatol. Published online September 13, 2022. doi:10.1111/jocd.15384